Indrayani Biotech Limited has officially confirmed April 28, 2026 as the record date for its ₹49.90 crore rights issue following the Rights Issue Committee meeting held on April 09, 2026. The company has formally communicated this decision to BSE Limited under Regulations 30 and 42 of SEBI Listing Regulations, finalizing all critical parameters for the partly paid-up rights issue.

Rights Issue Structure and Pricing

The committee has approved the issuance of 3,25,25,897 partly paid-up equity shares at ₹15 per share when fully paid up, including a premium of ₹5 per share. The rights issue follows a 5:7 entitlement ratio, meaning eligible shareholders will receive 5 rights equity shares for every 7 fully paid-up equity shares held as on the record date.

Payment Structure and Timeline

The partly paid-up structure requires payments in installments, with ₹3.75 payable on application and ₹11.25 through subsequent calls as determined by the Rights Issue Committee.

Issue Timeline and Trading Period

The rights issue will open on Wednesday, May 27, 2026, and close on Thursday, June 25, 2026. The on-market renunciation period will run from May 27 to June 16, 2026, while off-market renunciation must be completed to ensure rights entitlements are credited before the issue closing date.

Share Capital Impact

The rights issue will significantly expand the company's equity base, with outstanding equity shares increasing from 4,55,36,256 shares prior to the rights issue to 7,80,62,153 shares post-issue, assuming full subscription and payment of call monies.

Regulatory Compliance and Service Providers

The Rights Issue Committee meeting commenced at 5:50 PM IST and concluded at 7:15 PM IST on April 09, 2026. The company has appointed India Ratings and Research Private Limited as the monitoring agency and Axis Bank as the banker to the issue. A separate ISIN has been applied for rights entitlements, which will be credited to eligible shareholders' demat accounts through NSDL and CDSL prior to the issue opening date. Additional terms and conditions will be detailed in the Letter of Offer to be filed with SEBI and BSE Limited.

Indrayani Biotech Limited's board of directors concluded their meeting on April 9, 2026, with significant decisions regarding corporate restructuring and governance appointments. The meeting, which was previously scheduled and announced on April 6, 2026, addressed key strategic initiatives for the company's future growth.

Board Meeting Outcomes

The board meeting, held from 4:45 PM to 5:50 PM on April 9, 2026, resulted in two major decisions that will shape the company's operational structure and compliance framework.

Demerger Evaluation and Restructuring Committee

The board has given preliminary approval to explore the demerger of the company's food division into a separate entity. This strategic decision aims to unlock shareholder value through focused business operations and enhanced operational efficiency.

To oversee this complex process, the board has constituted a dedicated "Restructuring Committee" with comprehensive authority to manage all aspects of the demerger evaluation. The committee has been empowered to make necessary decisions and initiate required actions throughout the restructuring process.

Internal Auditor Appointment

In a separate governance decision, the board approved the appointment of M/S VAITHIANATHAN & ASSOCIATES, Chartered Accountants, as the company's Internal Auditor. This appointment covers an extended period of two financial years, demonstrating the company's commitment to robust internal audit processes.

Regulatory Compliance

The board meeting outcome was filed under Regulation 30 of SEBI (LODR) Regulations, 2015, ensuring proper disclosure of material events to stakeholders. The regulatory filing was executed by Ramya Ravi, Company Secretary and Compliance Officer, maintaining the company's commitment to transparent corporate governance practices.

These strategic decisions reflect Indrayani Biotech's focus on optimizing its business structure while strengthening internal governance mechanisms for sustainable growth.